Multisystem involvement and early onset of Danon’s disease in female children. Clinical cases

Danon’s disease (DD) is a rare multisystem disease caused by pathogenic variants in the LAMP2 gene. Men are characterized by a multisystemic Involvement, most often represented by a triad of symptoms: skeletal myopathy, cardiomyopathy (hypertrophic phenotype), and cognitive dysfunction. Women are more likely to have isolated heart disease. Given that women are less likely to have extracardiac manifestations, the diagnosis of the disease in females can be very difficult and untimely. In this article, we present 2 clinical cases of BD in adolescent girls, characterized by an early onset of the disease and a multisystem course.

1. Danon MJ, Oh SJ, DiMauro S, et al. Lysosomal glycogen storage disease with normal acid maltase. Neurology. 1981;31(1):51–57. DOI:10.1212/wnl.31.1.51.

2. Nishino I, Fu J, Tanji K, et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature. 2000;406(6798):906– 910. DOI:10.1038/35022604.

3. List of variants in gene LAMP2. Clin Var Miner database https://clinvarminer.genetics.utah.edu/variants-bygene/LAMP2/significance/any.htm (28 July 2023)

4. Yang Z, Funke BH, Cripe LH, et al. LAMP2 microdeletions in patients with Danon disease. Circ Cardiovasc Genet. 2010;3(2):129–137. DOI:10.1161/CIRCGENETICS.109.901785.

5. Boucek D, Jirikowic J, Taylor M. Natural history of Danon disease. Genet Med. 2011;13(6):563–568. DOI:10.1097/GIM.0b013e31820ad795.

6. Sugie K, Komaki H, Eura N, et al. A Nationwide Survey on Danon Disease in Japan. Int J Mol Sci. 2018;19(11):3507. Published 2018 Nov 8. DOI:10.3390/ijms19113507.

7. Prall FR, Drack A, Taylor M, et al. Ophthalmic manifestations of Danon disease. Ophthalmology. 2006;113(6):1010–1013. DOI:10.1016/j.ophtha.2006.02.030.

8. Brambatti M, Caspi O, Maolo A, et al. Danon disease: Gender differences in presentation and outcomes. Int J Cardiol. 2019;286:92–98. DOI:10.1016/j.ijcard.2019.01.020.

9. López-Sainz Á, Salazar-Mendiguchía J, García-Álvarez A, et al. Clinical Findings and Prognosis of Danon Disease. An Analysis of the Spanish Multicenter Danon Registry. Rev Esp Cardiol (Engl Ed). 2019;72(6):479–486. DOI:10.1016/j.rec.2018.04.035.

10. Lotan D, Salazar-Mendiguchía J, Mogensen J, et al. Clinical Profile of Cardiac Involvement in Danon Disease: A Multicenter European Registry. Circ Genom Precis Med. 2020;13(6):e003117. DOI:10.1161/CIRCGEN.120.003117.

11. Yang JM, Lee BH, Nam GB, et al. Long-Term Follow-Up of Peripheral Pigmentary Retinopathy in Asian Patients with Danon Disease. Genes (Basel). 2020;11(11):1356. DOI:10.3390/genes11111356.

12. Kousal B, Majer F, Vlaskova H, et al. Pigmentary retinopathy can indicate the presence of pathogenic LAMP2 variants even in somatic mosaic carriers with no additional signs of Danon disease. Acta Ophthalmol. 2021;99(1):61– 68. DOI:10.1111/aos.14478.

13. Jhaveri S, Herber J, Zahka K, et al. Arrhythmias and fasciculoventricular pathways in patients with Danon disease: A single center experience. J Cardiovasc Electrophysiol. 2019;30(10):1932–1938. DOI:10.1111/jce.14049.

14. Montañés ME, Granados MA, Valverde M, et al. Wolff Parkinson white pattern in Danon disease: When preexcitation is not what it seems. J Electrocardiol. 2020;62:161–164. DOI:10.1016/j.jelectrocard.2020.08.020.

15. Konrad T, Sonnenschein S, Schmidt FP, et al. Cardiac arrhythmias in patients with Danon disease. Europace. 2017;19(7):1204–1210. DOI:10.1093/europace/euw215.

16. Maron BJ, Roberts WC, Arad M, et al. Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA. 2009;301(12):1253–1259. DOI:10.1001/jama.2009.371.

17. Hong KN, Battikha C, John S, et al. Cardiac Transplantation in Danon Disease. J Card Fail. 2022;28(4):664–669. DOI: 10.1016/j.cardfail.2021.11.007.

18. Miani D, Taylor M, Mestroni L, et al. Sudden death associated with danon disease in women. Am J Cardiol. 2012;109(3):406–411. DOI: 10.1016/j.amjcard.2011.09.024.

19. Gourzi P, Pantou MP, Gkouziouta A, et al. A new phenotype of severe dilated cardiomyopathy associated with a mutation in the LAMP2 gene previously known to cause hypertrophic cardiomyopathy in the context of Danon disease. Eur J Med Genet. 2019;62(1):77–80. DOI: 10.1016/j.ejmg.2018.05.015.

20. Bertini E, Donati MA, Broda P, et al. Phenotypic heterogeneity in two unrelated Danon patients associated with the same LAMP-2 gene mutation. Neuropediatrics. 2005;36(5):309–313. DOI:10.1055/s-2005-872844.

21. Popa MA, Klingel K, Hadamitzky M, et al. An unusual case of severe myocarditis in a genetic cardiomyopathy: a case report. Eur Heart J Case Rep. 2020;4(4):1–7. Published 2020 Jun 9. DOI: 10.1093/ehjcr/ytaa124.

22. Bui YK, Renella P, Martinez-Agosto JA, et al. Danon disease with typical early-onset cardiomyopathy in a male: focus on a novel LAMP-2 mutation. Pediatric Transplantation. 2008;12(2):246–250. DOI: 10.1111/j.1399-3046.2007.00874.x.

23. Vaikhanskaya T, Sivitskaya L, Danilenko N. Danon disease: A rare systemic disorder with the LAMP2-cardiomyopathy Russ J Cardiol. 2017;10 (150): 93–99. In Russian DOI: 10.15829/1560-4071-2017-10-93-99.

24. Rossano J, Taylor M, Lin K, et al. Abstract 11117: Phase 1 Danon Disease Results: The First Single Dose Intravenous (IV) Gene Therapy (RP-A501) With Recombinant Adeno-Associated Virus (AAV9:LAMP2B) for a Monogenic Cardiomyopathy. Circulation. 2022;(146): 146:A11117. DOI: 10.1161/circ.146.suppl_1.11117Circulation.2022;146:A11117.